| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
Form 4: Hayden Michael R, Director
Bought 5,000 shares ($148K) |
| 09 Nov 2026 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
– ZANVASTROTM (zilganersen) first approved medicine for Alexander disease; first independent launch underway from leading neurology pipeline – |
| 23 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) |
| 21 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
– Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – |
| 19 Oct 2026 |
Form 4: Devers Shannon L., EVP, Chief Human Resources Ofc
Received 2,820 shares by exercise or conversion · Sold 1,357 shares ($59.1K) |
| 19 Oct 2026 |
Form 4: Swayze Eric, EVP Research
Received 125 shares by exercise or conversion · Sold 53 shares ($2.31K) |
| 16 Oct 2026 | 144 |
| 23 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential – |
| 04 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) |
| 04 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients |
| 02 Sep 2026 |
Form 4: Bennett C Frank, EVP, Chief Scientific Officer
Acquired 110 shares (Other Transaction) ($5.64K) |
| 02 Sep 2026 |
Form 4: O'neil Patrick R., EVP CLO & General Counsel
Acquired 63 shares (Other Transaction) ($3.23K) |
| 02 Sep 2026 |
Form 4: Monia Brett P, Director
Acquired 98 shares (Other Transaction) ($5.03K) |
| 02 Sep 2026 |
Form 4: Birchler Brian, EVP, Corp and Development Ops
Acquired 58 shares (Other Transaction) ($2.98K) |
| 31 Jul 2026 |
Form 4: Hayden Michael R, Director
Bought 15,000 shares ($801K) · Bought 5,000 shares ($258K) |
| 31 Jul 2026 | S-8 |
| 29 Jul 2026 | IONIS PHARMACEUTICALS, INC. 10-Q 06-30-2026 |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
- TRYNGOLZA® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population – |
| 17 Jul 2026 |
Form 4: Reikes Peter N, Director
Granted 3,399 Restricted Stock Unit |
Loading...